Lineage Cell Therapeutics
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. Based in Carlsbad.
Lineage Cell Therapeutics: net income sharply up (+90.4%), sales sharply down (−34.5%), operating income sharply up (+37.2%).
- Net income sharply upH1 2026
Net income: $−3M, vs. $−35M a year earlier, i.e. +90.4%.
- Sales sharply downH1 2026
Revenue: $3M, vs. $4M a year earlier, i.e. −34.5%.
- Operating income sharply upH1 2026
Operating income: $−17M, vs. $−26M a year earlier, i.e. +37.2%.
- Cash flow sharply downH1 2026
Operating cash flow: $−15M, vs. $−10M a year earlier, i.e. −47.0%.
What the market pays, vs. the sector
This company's valuation multiples history is being built day by day from now on.
P/E calculated on net income (trailing 12 months: last fiscal year + H1 2026 − same period a year earlier). Sector median: companies in the group tracked here. Prices: Yahoo Finance; market cap cross-checked with the Tel Aviv Stock Exchange for Israeli stocks. These ratios describe a price, not a value: none of them says whether the share is expensive or cheap.
Follow earnings · WhatsApp group TA-125Details ▾
Every report from a TA-125 company, analyzed the same day: key figures and year-on-year change, analysis in brief, share price reaction. One daily summary during earnings season.
Join the TA-125 groupDetailed figures and history
Financial summary
| S1 2026 | S1 2025 | FY 2025 | |
|---|---|---|---|
| Total assets | 106 | 91 | 113 |
| Current assets | 53 | 44 | 59 |
| Non-current assets | 53 | 47 | 53 |
| Equity | 60 | 47 | 43 |
| of which minority interests | −1 | −1 | −1 |
| Current liabilities | 8 | 11 | 11 |
| Non-current liabilities | 38 | 33 | 58 |
| Revenue | 3 | 4 | 15 |
| Gross profit | 3 | 4 | 14 |
| Operating income | −17 | −26 | −37 |
| Pre-tax income | −3 | −35 | −69 |
| Net income | −3 | −35 | −63 |
| Net income (attributable to shareholders) | −3 | −35 | −63 |
| Dividends paid | 0 | 0 | 0 |
| Operating cash flow | −15 | −10 | −19 |
In millions of dollars. The "H1" columns cover the first six months of the year.
Calculated from these figures
| S1 2026 | S1 2025 | FY 2025 | |
|---|---|---|---|
| Gross margin | 100.0% | 98.2% | 99.0% |
| Operating margin | −591.1% | −616.0% | −251.6% |
| Net margin | −119.2% | −810.9% | −434.2% |
| Current ratio (current assets / current liabilities) | 6,6 x | 4,1 x | 5,2 x |
| Equity / total assets | 56.3% | 51.9% | 38.5% |
The 5-year history, charts and cross-check models are coming for companies listed only in Tel Aviv: each new filing on Maya is kept and enriches the page.
Company overview
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1).
Source: official company profile (Yahoo Finance), summary. Website: www.lineagecell.com
- Maya, Tel Aviv Stock Exchange: company page and reports
No dividend paid over the past five years (source: Yahoo Finance).